Samyang Holdings Biopharm Group is set to expand into the global medical aesthetics market with its biodegradable polymer filler, Lafullen®?. Samyang Holdings signed a partnership agreement with Hangzhou Yxintent, a Chinese medical devices and aesthetics specialist company for the export of Lafullen®? at Samyang Discovery Center in Pangyo.

Through this contract, Yxintent will conduct clinical trials and obtain approval for Lafullen®? in China, and once approved, will exclusively sell Lafullen®? inChina.

Being the first Korean company entering the China's biodegradable polymer dermal filler market, Samyang Holdings plans to supply about KRW 100 billion worth of finished products over the next five years. With this export agreement with Yxintent, Samyang Holdings plans to take the lead in China's rapidly growing polymer filler market. Lafullen®?

is a dermal filler developed by Samyang Holdings Biopharm Group. It is primarily composed of biodegradable polymer substance called polycaprolactone (PCL) that has a duration of over two years. In 2021, it obtained approval and was recognized for its excellent qualities with its long-term effects and safety being published in a Scientific Citation Index (SCI) international academic journal.

Samyang Holdings has recently been intensifying its global entry into the filler market. In April, Lafullen®? obtained approval in Indonesia while discussing export contracts with many countries in Central and South America as well as Southeast Asia.